Contact this trialFirst, we need to learn more about you.
Small Molecule Inhibitor
MK-1084 + Pembrolizumab for Solid Cancers
Recruiting1 awardPhase 1
Edmonton, Alberta
This trial is testing a new drug called MK-1084, alone or with other treatments, in patients with advanced cancers that have a specific mutation. The drug aims to block this mutation to stop or slow down the cancer. Another drug, Sotorasib, was the first approved treatment for this type of cancer.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service